Quality of Life (QoL) in Non-Acute Vogt–Koyanagi–Harada Disease (VKHD) at Two Time Points 24 Months Apart

References

• Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Bost New England Medical Center; 1993.
   Google Scholar
• Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute visual function questionnaire. Arch Ophthalmol (Chicago, Ill 1960). 2001;119(7):1050–1058. doi:10.1001/archopht.119.7.1050.
   PubMed Web of Science ®Google Scholar
• Naik RK, Rentz AM, Foster CS, et al. Normative comparison of patient-reported outcomes in patients with noninfectious uveitis. JAMA Ophthalmol. 2013;131(2):219. doi:10.1001/2013.jamaophthalmol.102.
   PubMed Web of Science ®Google Scholar
• Lavezzo MM, Sakata VM, Morita C, et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis. 2016;11(1):29. doi:10.1186/s13023-016-0412-4.
   PubMedGoogle Scholar
• Souto FMS, Missaka RFBG, Magalhães BM, et al. Impact of inflammation and treatment on self-reported quality of life in patients with non-acute Vogt-Koyanagi-Harada disease (VKHD). Ocul Immunol Inflamm. 2021;29(1):137–148. doi:10.1080/09273948.2019.1668431.
   PubMed Web of Science ®Google Scholar
• Sakai T, Watanabe H, Kuroyanagi K, et al. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis. Br J Ophthalmol. 2013;97(3):338–342. doi:10.1136/bjophthalmol-2012-302515.
   PubMed Web of Science ®Google Scholar
• Sheppard J, Joshi A, Betts KA, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017;135(6):511. doi:10.1001/jamaophthalmol.2017.0603.
   PubMed Web of Science ®Google Scholar
• Venkataraman A, Rathinam SR. A pre- and post-treatment evaluation of vision-related quality of life in uveitis. Indian J Ophthalmol. 2008;56(4):307–312. doi:10.4103/0301-4738.39662.
   PubMed Web of Science ®Google Scholar
• Kaleemunnisha S, Sudharshan S, Biswas J. Quality of life in non-infectious uveitis patients on immunosuppressive therapy. Middle East Afr J Ophthalmol. 2014;21(3):225–231. doi:10.4103/0974-9233.134675.
   PubMedGoogle Scholar
• Niemeyer KM, Gonzales JA, Rathinam SR, et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. Am J Ophthalmol. 2017;179:10–17. doi:10.1016/j.ajo.2017.04.003
   PubMed Web of Science ®Google Scholar
• Missaka RFBG, Souto FMS, de Albornoz NCA, et al. Self-reported quality of life in patients with long-standing Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2020;28(3):409–420. doi:10.1080/09273948.2019.1595672.
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–652. doi:10.1016/s0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar
• Simão LM, Lana-Peixoto MA, Araújo CR, Moreira MA, Teixeira AL. The Brazilian version of the 25-Item National Eye Institute visual function questionnaire: translation, reliability and validity. Arq Bras Oftalmol. 2008;71(4):540–546. doi:10.1590/s0004-27492008000400014.
   PubMed Web of Science ®Google Scholar
• Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR. Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36). Rev Bras Reumatol. 1999;39:143–150.
   Google Scholar
• Robson AG, Frishman LJ, Grigg J, et al. ISCEV Standard for full-field clinical electroretinography (2022 update). Doc Ophthalmol. 2022 Jun;144(3):165–177.
   PubMed Web of Science ®Google Scholar
• da Silva FT, Hirata CE, Olivalves E, Oyamada MK, Yamamoto JH. Fundus-based and electroretinographic strategies for stratification of late-stage Vogt-Koyanagi-Harada disease patients. Am J Ophthalmol. 2009;148(6):939–945.e3. doi:10.1016/j.ajo.2009.06.029.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Herbort CP, Khairallah M. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30(5):539–552. doi:10.1007/s10792-008-9263-x.
   PubMedGoogle Scholar
• Mouelhi Y, Jouve E, Castelli C, Gentile S. How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods. Health Qual Life Outcomes. 2020;18(1):136. doi:10.1186/s12955-020-01344-w.
   PubMed Web of Science ®Google Scholar
• Wells GA, Russell AS, Haraoui B, Bissonnette R, Ware CF. Validity of quality of life measurement tools–from generic to disease-specific. J Rheumatol Suppl. 2011;88:2–6. doi:10.3899/jrheum.110906.
   PubMedGoogle Scholar
• Qian Y, Glaser T, Esterberg E, Acharya NR. Depression and visual functioning in patients with ocular inflammatory disease. Am J Ophthalmol. 2012;153(2):370–378.e2. doi:10.1016/j.ajo.2011.06.028.
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol (Chicago, Ill 1960). 2001;119(6):841–849. doi:10.1001/archopht.119.6.841.
   PubMed Web of Science ®Google Scholar
• Lescrauwaet B, Miserocchi E, Thurau S, et al. Association between visual function response and reduction of inflammation in noninfectious uveitis of the posterior segment. Invest Ophthalmol Vis Sci. 2017;58(9):3555–3562. doi:10.1167/iovs.17-22049.
   PubMed Web of Science ®Google Scholar
• Hoeksema L, Los LI. Vision-related quality of life in patients with inactive HLA-B27-associated-spectrum anterior uveitis. PLoS One. 2016;11(1):e0146956. doi:10.1371/journal.pone.0146956.
   PubMed Web of Science ®Google Scholar
• Haasnoot A-MJW, Sint Jago NFM, Tekstra J, de Boer JH. Impact of uveitis on quality of life in adult patients with Juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2017;69(12):1895–1902. doi:10.1002/acr.23224.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Mosconi P, Colucci A, Bandello F. Quality of life in patients with uveitis on chronic systemic immunosuppressive treatment. Ocul Immunol Inflamm. 2010;18(4):297–304. doi:10.3109/09273941003637510.
   PubMed Web of Science ®Google Scholar
• Kuiper JJW, Missotten T, Baarsma SG, Rothova A. Vision-related quality of life in patients with birdshot chorioretinopathy. Acta Ophthalmol. 2013;91(4):e329–31. doi:10.1111/aos.12054.
   PubMed Web of Science ®Google Scholar
• Arruda JSD, Tibúrcio JD, de Campos-Carli SM, Teixeira AL, Vasconcelos-Santos DV. Vision-related quality of life and depression in Brazilian patients with toxoplasmic retinochoroiditis. Int J Infect Dis. 2021;112:66–72. doi:10.1016/j.ijid.2021.08.051.
   PubMed Web of Science ®Google Scholar
• Verhagen FH, Wijnhoven R, Ossewaarde-van Norel J, et al. Prevalence and characteristics of ocular pain in non-infectious uveitis: a quality of life study. Br J Ophthalmol. 2018;102(8):1160–1166. doi:10.1136/bjophthalmol-2017-311575.
   PubMed Web of Science ®Google Scholar
• Kappel PJ, Monnet D, Yu F, Brezin AP, Levinson RD, Holland GN. Contrast sensitivity among patients with birdshot chorioretinopathy. Am J Ophthalmol. 2009;147(2):351–356.e2. doi:10.1016/j.ajo.2008.08.021.
   PubMed Web of Science ®Google Scholar
• Marmor MF. Contrast sensitivity versus visual acuity in retinal disease. Br J Ophthalmol. 1986;70(7):553–559. doi:10.1136/bjo.70.7.553.
   PubMed Web of Science ®Google Scholar
• Shah KH, Holland GN, Yu F, Van Natta M, Nusinowitz S. Contrast sensitivity and color vision in HIV-infected individuals without infectious retinopathy. Am J Ophthalmol. 2006;142(2):284–292.e2. doi:10.1016/j.ajo.2006.03.046.
   PubMed Web of Science ®Google Scholar
• Murphy CC. Quality of life and visual function in patients with intermediate uveitis. Br J Ophthalmol. 2005;89(9):1161–1165. doi:10.1136/bjo.2005.067421.
   PubMed Web of Science ®Google Scholar
• Souto FMS, Lavezzo MM, Oyamada MK, Yamamoto JH. Vogt-Koyanagi-Harada disease after discontinuation of systemic treatment. Clin Exp Ophthalmol. 2022;50:569–572. doi:10.1111/CEO.14081.
   PubMed Web of Science ®Google Scholar